The New England journal of medicine, 2021-01, Vol.384 (3), p.238-251
- Weinreich, David M
- Sivapalasingam, Sumathi
- Norton, Thomas
- Ali, Shazia
- Gao, Haitao
- Bhore, Rafia
- Musser, Bret J
- Soo, Yuhwen
- Rofail, Diana
- Im, Joseph
- Perry, Christina
- Pan, Cynthia
- Hosain, Romana
- Mahmood, Adnan
- Davis, John D
- Turner, Kenneth C
- Hooper, Andrea T
- Hamilton, Jennifer D
- Baum, Alina
- Kyratsous, Christos A
- Kim, Yunji
- Cook, Amanda
- Kampman, Wendy
- Kohli, Anita
- Sachdeva, Yessica
- Graber, Ximena
- Kowal, Bari
- DiCioccio, Thomas
- Stahl, Neil
- Lipsich, Leah
- Braunstein, Ned
- Herman, Gary
- Yancopoulos, George D
2021
Details
- Autor(en) / Beteiligte
- Weinreich, David M
- Sivapalasingam, Sumathi
- Norton, Thomas
- Ali, Shazia
- Gao, Haitao
- Bhore, Rafia
- Musser, Bret J
- Soo, Yuhwen
- Rofail, Diana
- Im, Joseph
- Perry, Christina
- Pan, Cynthia
- Hosain, Romana
- Mahmood, Adnan
- Davis, John D
- Turner, Kenneth C
- Hooper, Andrea T
- Hamilton, Jennifer D
- Baum, Alina
- Kyratsous, Christos A
- Kim, Yunji
- Cook, Amanda
- Kampman, Wendy
- Kohli, Anita
- Sachdeva, Yessica
- Graber, Ximena
- Kowal, Bari
- DiCioccio, Thomas
- Stahl, Neil
- Lipsich, Leah
- Braunstein, Ned
- Herman, Gary
- Yancopoulos, George D
- Titel
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- Ist Teil von
- The New England journal of medicine, 2021-01, Vol.384 (3), p.238-251
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- An anti–SARS-CoV-2 antibody cocktail was given to patients within 3 days after PCR confirmation of Covid-19. In patients who were antibody-negative at baseline, treatment was associated with rapid viral clearance and potentially with a less frequent need for medical attention. The effect was less marked among patients who were antibody-positive at baseline.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2035002Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7781102
- Format
- –
- Schlagworte
- Adult, Adverse events, Antibodies, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Antibodies, Neutralizing - adverse effects, Antibodies, Neutralizing - therapeutic use, Clinical medicine, Coronaviridae, Coronaviruses, COVID-19, COVID-19 - diagnosis, COVID-19 - drug therapy, COVID-19 - virology, Double-Blind Method, Drug Combinations, Female, Humans, Hypersensitivity, Hypotheses, Hypothesis testing, Immune response, Immunologic Factors - adverse effects, Immunologic Factors - therapeutic use, Least-Squares Analysis, Male, Medical examination, Middle Aged, Monoclonal antibodies, Original, Outpatients, Pharmacokinetics, Placebos, Proteins, Resistant mutant, Reverse Transcriptase Polymerase Chain Reaction, SARS-CoV-2 - genetics, SARS-CoV-2 - isolation & purification, Severe acute respiratory syndrome coronavirus 2, Spike protein, Statistical analysis, Testing, Viral Load - drug effects